Intervacc Investor Relations Material
Latest events
Q3 2024
Intervacc
Q1 2025
14 May, 2025
Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Intervacc
Access all reports
Intervacc AB, a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company offers Canvax, a vaccine for bovine viral diarrhea; and Fervac B, a vaccine for feline viral rhinotracheitis, calicivirus, and panleukopenia. It also provides a range of potential prevention vaccines to veterinarians, including vaccines to control rabies. Intervacc is based in Hägersten, Sweden.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IVACC
Country
🇸🇪 Sweden